C4 Therapeutics, Inc. CCCC

CCCC Company Overview

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a therapeutic approach designed to eliminate disease-causing proteins rather than inhibit them. The company operates within the biotechnology and precision medicine industries, with a primary emphasis on oncology. Its proprietary platform is built around targeted protein degrader technologies, including bifunctional degrader molecules intended to harness the body’s natural ubiquitin-proteasome system to selectively degrade proteins associated with cancer and other diseases.

The company’s primary value drivers are its internally developed oncology pipeline, platform licensing arrangements, and strategic research collaborations with larger pharmaceutical companies. Key programs have focused on targets such as IKZF1/3, BRAF, and EGFR mutations associated with solid tumors and hematologic malignancies. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics evolved from academic and scientific advances in targeted protein degradation developed by founders and researchers associated with the Dana-Farber Cancer Institute and related scientific institutions. The company completed its initial public offering in 2020 and has continued expanding its degrader platform through partnerships and internal R&D.